Cedarbaum, Jesse M.

The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function

Cedarbaum, J. M., Stambler, N., Malta, E., Fuller, C., Hilt, D., Thurmond, B., & Nakanishi, A. (1999) · Journal of the Neurological Sciences

Amyotrophic Lateral Sclerosis ResearchNeurogenetic and Muscular Disorders Research

Cited by 3,307

Neuropsychiatric symptoms in Alzheimer's disease

Lyketsos, C. G., Carrillo, M. C., Ryan, J. M., Khachaturian, A. S., Trzepacz, P., Amatniek, J., Cedarbaum, J., Brashear, R., & Miller, D. S. (2011) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 1,139

Mild cognitive impairment: Disparity of incidence and prevalence estimates

Ward, A., Arrighi, H. M., Michels, S., & Cedarbaum, J. M. (2012) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchCancer-related cognitive impairment studies

Cited by 569

2014 Update of the Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception

Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Cedarbaum, J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., et al. (2015) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 348

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease

Salloway, S., Sperling, R., Keren, R., Porsteinsson, A. P., van Dyck, C. H., Tariot, P. N., Gilman, S., Arnold, D., Abushakra, S., Hernandez, C., et al. (2011) · Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 258

Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial

Coric, V., Salloway, S., van Dyck, C. H., Dubois, B., Andreasen, N., Brody, M., Curtis, C., Soininen, H., Thein, S., Shiovitz, T., et al. (2015) · JAMA Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 240

Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force

Vellas, B., Carrillo, M. C., Sampaio, C., Brashear, H. R., Siemers, E., Hampel, H., Schneider, L. S., Weiner, M., Doody, R., Khachaturian, Z., et al. (2013) · Alzheimer's & Dementia

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 147

Using a smartwatch and smartphone to assess early Parkinson’s disease in the WATCH-PD study

Adams, J. L., Kangarloo, T., Tracey, B., O’Donnell, P., Volfson, D., Latzman, R. D., Zach, N., Alexander, R., Bergethon, P., Cosman, J., et al. (2023) · npj Parkinson's Disease

Parkinson's Disease Mechanisms and TreatmentsContext-Aware Activity Recognition Systems

Cited by 98

The qualification of an enrichment biomarker for clinical trials targeting early stages of Parkinson’s disease

Stephenson, D., Hill, D., Cedarbaum, J. M., Tome, M., Vamvakas, S., Romero, K., Conrado, D. J., Dexter, D. T., Seibyl, J., Jennings, D., et al. (2019) · Journal of Parkinson’s Disease

Parkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment Research

Cited by 46

Mapping Relevance of Digital Measures to Meaningful Symptoms and Impacts in Early Parkinson’s Disease

Mammen, J. R., Speck, R. M., Stebbins, G. M., Müller, M. L. T. M., Yang, P. T., Campbell, M., Cosman, J., Crawford, J. E., Dam, T., Hellsten, J., et al. (2023) · Journal of Parkinson’s Disease

Parkinson's Disease Mechanisms and TreatmentsHealth Education and Validation

Cited by 38

Accelerating Parkinson’s Disease drug development with federated learning approaches

Khanna, A., Adams, J., Antoniades, C., Bloem, B. R., Carroll, C., Cedarbaum, J., Cosman, J., Dexter, D. T., Dockendorf, M. F., Edgerton, J., et al. (2024) · npj Parkinson's Disease

Privacy-Preserving Technologies in DataParkinson's Disease Mechanisms and Treatments

Cited by 21